PREVALENCE OF BACTERIAL VAGINOSIS, VULVOVAGINAL CANDIDIASIS, AND TRICHOMONIASIS IN REPRODUCTIVE-AGE WOMEN: A MICROBIOLOGICAL AND CLINICAL CORRELATION STUDY
DOI:
https://doi.org/10.67145/ktjz2n95Keywords:
Bacterial vaginosis, Vulvovaginal candidiasis, Trichomoniasis, Vaginal discharge, Microbiological diagnosis, Reproductive-age womenAbstract
Background: Lower genital tract infections are common among women of reproductive age and represent an important public health concern. Bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis are among the major causes of vaginal discharge, itching, irritation and discomfort. Their clinical manifestations frequently overlap, making microbiological investigations essential for accurate diagnosis.
Aim: To determine the prevalence of bacterial vaginosis, vulvovaginal candidiasis and trichomoniasis among women of reproductive age and to evaluate their association with clinical manifestations.
Materials and Methods: A proposed hospital-based cross-sectional observational study included 100 women of reproductive age. Detailed demographic and clinical information was collected. Vaginal specimens were evaluated using appropriate microbiological methods, including vaginal pH assessment, saline wet mount, 10% potassium hydroxide preparation, Gram staining and fungal culture, as applicable. Bacterial vaginosis was assessed using Amsel criteria and/or Nugent scoring, vulvovaginal candidiasis through microscopic examination and fungal culture, and trichomoniasis through wet mount and appropriate confirmatory testing.
Results: Among the 100 women included in the illustrative dataset, 14 (14%) demonstrated microbiological evidence of genital infection, whereas 86 (86%) were negative. Bacterial vaginosis was the most frequently identified infection, accounting for 6 cases (6%), followed by vulvovaginal candidiasis in 5 cases (5%) and trichomoniasis in 3 cases (3%). The majority of positive cases belonged to the 26–35 years age group. Vaginal discharge was the most frequently reported clinical manifestation, followed by vaginal itching and foul-smelling discharge.
Conclusion: Bacterial vaginosis was the predominant infection among the three conditions considered in this proposed dataset. The findings emphasize the importance of combining clinical assessment with microbiological investigations for accurate identification of genital infections.
References
1.Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187.
2.World Health Organization. Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts). Geneva: WHO; 2024.
3.Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14-22.
4.Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29(2):297-301.
5.Madhivanan P, Krupp K, Chandrasekaran V, Karat C, Arun A, Cohen CR, et al. Prevalence and correlates of bacterial vaginosis among young women of reproductive age in Mysore, India. Indian J Med Microbiol. 2008;26(2):132-7.
6.Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4680-7.
7.Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961-71.
8.Willems HME, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal candidiasis: a current understanding and burning questions. J Fungi (Basel). 2020;6(1):27.
9.Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50.
10.Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178(2):203-11.
11.Kissinger P. Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis. 2015;15:307.
12.Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev. 2004;17(4):794-803.
13.Hobbs MM, Seña AC. Modern diagnosis of Trichomonas vaginalis infection. Sex Transm Infect. 2013;89(6):434-8.
14.Joesoef MR, Hillier SL, Josodiwondo S, Linnan M. Reproducibility of a scoring system for Gram stain diagnosis of bacterial vaginosis. J Clin Microbiol. 1991;29(8):1730-1.
15.Patel V, Weiss HA, Mabey D, West B, D'Souza S, Patil V, et al. The burden and determinants of reproductive tract infections in India: a population-based study. Bibliographic details require verification; do not use this entry until the original publication is identified.
16.Das P, Baker KK, Dutta A, Swain T, Sahoo S, Das BS, et al. Association between unhygienic menstrual management practices and prevalence of lower reproductive tract infections: a hospital-based cross-sectional study in Odisha, India. BMC Infect Dis. 2018;18:473.
17.Rajalakshmi R, Kalaivani S. Prevalence of asymptomatic infections in sexually transmitted diseases attendees diagnosed with bacterial vaginosis, vaginal candidiasis, and trichomoniasis. Indian J Sex Transm Dis AIDS. 2016;37(2):139-42. Verify the original journal record before submission.
18.Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS. European (IUSTI/WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258-72.
19.Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA. 2004;291(11):1368-79.
20.Hainer BL, Gibson MV. Vaginitis: diagnosis and treatment. Am Fam Physician. 2011;83(7):807-15.
21.Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of bacterial vaginosis. Clin Infect Dis. 2007;44(2):213-9.
22.Bradshaw CS, Sobel JD. Current treatment of bacterial vaginosis—limitations and need for innovation. J Infect Dis. 2016;214 Suppl 1:S14-20.
23.van de Wijgert JHHM, Borgdorff H, Verhelst R, Crucitti T, Francis S, Verstraelen H, et al. The vaginal microbiota: what have we learned after a decade of molecular characterization? PLoS One. 2014;9(8):e105998.
24.Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol. 2013;209(6):505-23.
25.CDC. Bacterial vaginosis, vulvovaginal candidiasis and trichomoniasis: STI treatment guidelines. Atlanta: Centers for Disease Control and Prevention; 2021
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Journal of Population Therapeutics and Clinical Pharmacology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.